Molecular Atlas of Lung Development Program (LungMAP) Phase 3 - Research Centers (U01 Clinical Trial Not Allowed)

Funding Opportunity RFA-HL-24-006 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to support the Molecular Atlas of Lung Development Program (LungMAP) Phase 3 Research Centers (RCs). The overall goal of LungMAP is to build a comprehensive molecular and cellular atlas of the human lung to serve as a reference platform to better understand both normal biology and disease pathobiology, and to identify critical cellular components, molecular pathways, and novel therapeutic targets in lung disease. RCs will be expected to obtain and analyze pediatric and adult lung tissues in order to generate high-resolution molecular profiling data of the diseased lung. RCs will perform integrated data analysis, explore mechanisms of disease pathogenesis, collaborate closely with other LungMAP teams and to disseminate this resource to the broader research community. Applicants are not required to have been funded in LungMAP Phase 2 (RFA-HL-19-020) in order to submit applications to this NOFO.